Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Int Forum Allergy Rhinol. 2014 Jul 12;4(9):725–733. doi: 10.1002/alr.21350

Table 1.

Comparison of Baseline Characteristics of Medical and Surgical Cohorts

Medical treatment (n=58) Surgical treatment (n=222)
Demographics: Mean (SD) N(%) Mean (SD) N (%) p-value
Follow-up (mos.) 11.6 (5.3) 12.1 (5.6) 0.543
Age (yrs) 50.3 (15.0) 51.9 (14.6) 0.487
Males 23 (39.7) 119 (53.6)
Females 35 (60.3) 103 (46.4) 0.358
White/Caucasian 51 (87.9) 187 (84.2) 0.438
African American 3 (5.2) 12 (5.4) >0.999
Asian 1 (1.7) 9 (4.1) 0.693
American Indian/Native Alaskan 2 (3.4) 1 (0.5) 0.110
Hispanic/Latino 0 (0.0) 13 (5.9) 0.077
Medical comorbidity:
Asthma 15 (25.9) 84 (37.8) 0.089
Nasal polyposis 20 (34.5) 80 (36.0) 0.826
Allergies (test confirmed) 20 (34.5) 88 (39.6) 0.472
ASA sensitivity 6 (10.3) 16 (7.2) 0.429
Depression 12 (20.7) 42 (18.9) 0.761
Tobacco use 1 (1.7) 13 (5.9) 0.314
Previous sinus surgery 34 (58.6) 120 (54.1) 0.534
Baseline disease severity:
SNOT-22 score 46.3 (18.3) 52.9 (19.0) 0.018
RSDI score 38.3 (23.5) 46.2 (25.0) 0.030
  RSDI physical score 16.6 (9.5) 18.2 (9.0) 0.248
  RSDI functional score 12.3 (7.9) 15.1 (9.0) 0.030
  RSDI emotional score 9.4 (8.1) 12.9 (9.0) 0.007
Computed tomography score 13.4 (6.0) 12.1 (5.8) 0.132
Endoscopy score 6.9 (4.3) 6.0 (3.8) 0.128
B-SIT olfaction score 8.8 (3.2) 9.0 (3.2) 0.703

SD, standard deviation; mos., months; yrs, years; ASA, acetylsalicylic acid, SNOT-22, 22-item SinoNasal Outcome Test; RSDI, Rhinosinusitis Disability Index, B-SIT, Brief Smell Identification Test